Amylyx (AMLX) stock soared 21% after avexitide succeeded in Phase 3 trial. Mizuho raises target to $30 with 2027 launch expected. Full trial results inside. The post Amylyx (AMLX) Stock Surges Past 52-Week High on Successful Avexitide Phase 3 Results appeared first on Blockonomi.